Former FDA ODE II Director Meyer Building New Regulatory Sciences Center at UVA
This article was originally published in RPM Report
Executive Summary
Bob Meyer, a veteran of both sides of the FDA drug regulatory process from top-level positions in FDA’s drug review office and the Merck regulatory strategy and policy group, is trying to create a new regulatory science center at the University of Virginia that could add to FDA’s close-by academic support resources.
You may also be interested in...
Good Neighbors Make Good Regulatory Science Centers, FDA Decides
Georgetown, Maryland gain CERSI grants in part because of their proximity to agency staff.
Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?
FDA's drug review managers and staff are showing signs of wear and tear from the tough political climate for the agency. Some key staff have departed. Merck took advantage of the turmoil to get a manager with knowledge of the endocrine area, where the taranabant NDA will be filed.
FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus
CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.